Last reviewed · How we verify
nasal mupirocin
nasal mupirocin is a Small molecule drug developed by Natividad Medical Center. It is currently in Phase 1 development. Also known as: Bactrban Nasal.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | nasal mupirocin |
|---|---|
| Also known as | Bactrban Nasal |
| Sponsor | Natividad Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients (PHASE4)
- STaph Aureus Resistance-Treat Early and Repeat (STAR-TER) (PHASE2)
- Bacterial Decolonization Plus Intraoperative Angiography for Soft Tissue Sarcomas Receiving Preoperative Radiotherapy (CONCERTO) (PHASE2)
- Effectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients
- Staph Intervention for Effective Local Defense (PHASE4)
- Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance (NA)
- Optimal Treatment of MRSA Throat Carriers (PHASE3)
- Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- nasal mupirocin CI brief — competitive landscape report
- nasal mupirocin updates RSS · CI watch RSS
- Natividad Medical Center portfolio CI
Frequently asked questions about nasal mupirocin
What is nasal mupirocin?
Who makes nasal mupirocin?
Is nasal mupirocin also known as anything else?
What development phase is nasal mupirocin in?
Related
- Manufacturer: Natividad Medical Center — full pipeline
- Also known as: Bactrban Nasal
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing